• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Repare Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/8/25 7:05:27 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPTX alert in real time by email
    8-K
    0001808158false00-000000000018081582025-08-082025-08-08

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 08, 2025

     

     

    Repare Therapeutics Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Quebec

    001-39335

    Not applicable

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    7171 Frederick-Banting, Building 2

    Suite 270

     

    St-Laurent, Quebec, Canada

     

    H4S 1Z9

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 857 412-7018

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common shares, no par value

     

    RPTX

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On August 8, 2025, Repare Therapeutics Inc. (the "Company") issued a press release announcing its recent business highlights and financial results for the three and six months ended June 30, 2025. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

    The information contained herein and in the accompanying exhibits is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

     

    The Company’s website and any information contained on the Company’s website are not incorporated into this Current Report on Form 8-K

    Item 9.01 Financial Statements and Exhibits.

    Exhibit

    No.

    Description

    99.1

    Press Release dated August 8, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    REPARE THERAPEUTICS INC.

     

     

     

     

    Date:

    August 8, 2025

    By:

    /s/ Steve Forte

     

     

     

    Steve Forte
    President, Chief Executive Officer and Chief Financial Officer

     


    Get the next $RPTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RPTX

    DatePrice TargetRatingAnalyst
    6/9/2023$11.00 → $16.00Hold → Buy
    Stifel
    2/3/2023$28.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2023$28.00Overweight
    CapitalOne
    4/12/2022$11.00Buy → Hold
    Stifel
    3/17/2022$43.00Buy
    Goldman
    9/23/2021$48.00Buy
    Stifel
    9/13/2021$54.00Buy
    HC Wainwright & Co.
    8/16/2021$45.00 → $47.00Overweight
    Morgan Stanley
    More analyst ratings

    $RPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Finance and CAO Alves Sandra Isabelle Barros was granted 4,100 shares, increasing direct ownership by 16% to 29,622 units (SEC Form 4)

    4 - Repare Therapeutics Inc. (0001808158) (Issuer)

    4/29/25 5:07:34 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Alves Sandra Isabelle Barros claimed ownership of 25,522 shares (SEC Form 3)

    3 - Repare Therapeutics Inc. (0001808158) (Issuer)

    4/29/25 5:05:52 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, CHIEF FINANCIAL OFFICER Forte Steve

    4 - Repare Therapeutics Inc. (0001808158) (Issuer)

    4/4/25 4:15:09 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Entered into worldwide licensing agreement with Debiopharm for lunresertib Evaluating strategic alternatives to maximize shareholder value Initial data for LIONS and POLAR trials expected to be reported in Q4 2025 $109.5 million in cash and cash equivalents and marketable securities Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2025. "We remain focused on exploring strategic alternatives and partnerships across our portfolio to enhance long-term shareholder value, as exemplified by our recent worldwide licensing agreement with Debiopharm for lun

    8/8/25 7:00:00 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. ("Debiopharm"), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. "The exclusive worldwide licensing agreement with Debiopharm allows for the continued development of lunresertib, a novel PKMYT1 inhibitor, that has demonstrated encouraging results across multiple clinical trials in difficult-to-treat s

    7/15/25 4:05:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    SEC Filings

    View All

    SEC Form 10-Q filed by Repare Therapeutics Inc.

    10-Q - Repare Therapeutics Inc. (0001808158) (Filer)

    8/8/25 7:15:49 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Repare Therapeutics Inc. (0001808158) (Filer)

    8/8/25 7:05:27 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Repare Therapeutics Inc. (0001808158) (Filer)

    7/16/25 5:07:29 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bvf Partners L P/Il bought $6,249,889 worth of shares (1,227,301 units at $5.09) (SEC Form 4)

    4 - Repare Therapeutics Inc. (0001808158) (Issuer)

    11/17/23 4:54:43 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bvf Partners L P/Il bought $2,821,352 worth of shares (783,709 units at $3.60) (SEC Form 4)

    4 - Repare Therapeutics Inc. (0001808158) (Issuer)

    11/3/23 5:37:44 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Repare Therapeutics upgraded by Stifel with a new price target

    Stifel upgraded Repare Therapeutics from Hold to Buy and set a new price target of $16.00 from $11.00 previously

    6/9/23 7:34:45 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Repare Therapeutics from Overweight to Equal-Weight and set a new price target of $15.00 from $28.00 previously

    2/3/23 7:35:18 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CapitalOne initiated coverage on Repare Therapeutics with a new price target

    CapitalOne initiated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $28.00

    1/6/23 8:30:21 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

    SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

    11/14/24 9:00:57 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

    SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

    11/14/24 5:05:19 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

    SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

    11/14/24 9:42:55 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Leadership Updates

    Live Leadership Updates

    View All

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

    Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D             First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effecti

    5/7/24 4:05:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board. "On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare

    4/26/24 4:05:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Financials

    Live finance-specific insights

    View All

    Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

    Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

    5/1/25 7:00:00 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

    Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte

    12/12/24 4:20:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

    Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,

    12/10/24 4:05:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care